Site Search

1. 231.
   AMP/assets/File/education/MIMP/SolidTumors_Hereditary.pdf?pass=93

   Syndrome MLH1, MSH2, MSH6, PMS2 (germline) LOF 40-60% lifetime risk of endometrial cancer SGA, NGS Eye Retinoblastoma RB1 LOF risk of hereditary cancer SGA, NGS GI Tract Hereditary Diffuse Gastric CA CDH1 (E-Cadherin) LOF risk of hereditary cancer SGA, NGS Gastrointestinal Stromal Tumor (GIST) SDHA, SDHB, SDHC, SDHD; KIT, PDGFRA LOF; Activating

   https://www.amp.org/AMP/assets/File/education/MIMP/SolidTumors_Hereditary.pdf?pa...
2. 232.
   AMP/assets/File/education/MIMP/Colorectal.pdf?pass=12

   Lynch Syndrome; 1% of cancers with V600E mutations (and loss of MLH1) are Lynch Syndrome. Patients with strong family history should not be excluded from germline screening based on BRAF V600E mutations. HER2 Amplification/Overexpression Therapy selection Consideration of anti-HER2 therapy when RAS and BRAF are WT (1) IHC, FISH or NGS NTRK (extremely rare

   https://www.amp.org/AMP/assets/File/education/MIMP/Colorectal.pdf?pass=12
3. 233.
   AMP/assets/File/join/NonUSAffiliate_AGREEMENT_FORM.pdf?pass=57

   Independent application (without a long-term AMP member* sponsor): At least 5% of the total number of Affiliate members (the minimum number of active AMP members will not be fewer than three) b. Application with a long-term AMP member sponsor*: At least one active AMP member AND the continued sponsorship of a long-term AMP member * A long-term AMP member

   https://www.amp.org/AMP/assets/File/join/NonUSAffiliate_AGREEMENT_FORM.pdf?pass=...
4. 234.
   AMP/assets/File/clinical-practice/Provider-Friendly_BiomarkerReportTemplate.pdf...

   Date of birth (DOB): Sex: Gender: Test: Tumor Type: Specimen Type: Specimen No.: Percentage neoplastic cells: %Collection date: Received date: Report date: Report status: MOLECULAR BIOMARKER REPORTMOLECULAR BIOMARKER RESULT SUMMARY GENOMIC SIGNATURES RESULT SUMMARY*Tier* Variant DetectedAlteration TypeAllele Frequency (VAF)† /Copy Number‡Level of

   https://www.amp.org/AMP/assets/File/clinical-practice/Provider-Friendly_Biomarke...
5. 235.
   AMP/assets/File/education/MIMP/Thyroid.pdf?pass=88

   V600E in ~45% PTC) NGS, pyrosequencing, Sanger sequencing, or PCR-based genotyping assays with different sensitivity Prognosis Higher risk of recurrence in PTC, especially when it is with TERT promoter mutation Kinase inhibitor therapy selection/response prediction Consideration of BRAF-targeted therapy in metastatic disease not amenable to RAI therapy RAS

   https://www.amp.org/AMP/assets/File/education/MIMP/Thyroid.pdf?pass=88
6. 236.
   Microsoft Word - 2008CommitteesAnnualReport_Compiled.doc

   It was a tremendous success, with 236 registered attendees who had a very high interest level (99% had the webinar on their computer as for primary viewing during the session). The rating for whether the webinar met its objectives was 4.19 out of a possible score of 5. T&E will be hosting quarterly formal webinars and adhoc webinars as hot topics arise from

   https://www.amp.org/AMP/assets/File/committees/reports/2008CommitteesAnnualRepor...
7. 237.
   Laboratory Careers in Molecular Pathology - Association for Molecular Pathology

   Learn how laboratory professionals contribute to patient care and join the team that provides up to 70% of medical diagnoses. Download PDF. Corporate Partners Diamond Partner Diamond Partner Platinum Partner Gold Partner Gold Partner Gold Partner Gold Partner Gold Partner Gold Partner Gold Partner Gold Partner Diamond Partner Diamond Partner Silver Partner

   https://www.amp.org/education/career-development/laboratory-careers-in-molecular...
8. 238.
   Join/Renew - Association for Molecular Pathology

   For one year, their dues are discounted by 50%. Early-career membership is not available for new regular members. Early-career members are eligible to vote, to hold elected office and to serve on AMP committees. Category Dues Print Journal Early-career — Residing in High-Income Country $100 Available for purchase ($35) Early-career — Residing in an

   https://www.amp.org/membership/join-renew/
9. 239.
   AMP/assets/File/position-statements/2016/AMP-CAPComments_APCandMUTYHGeneTesting...

   However, it is important to note that approximately 5% of individuals with AFAP or MAP may present with 10-19 polyps, and language should be incorporated in the LCD that covers testing when indicated in these cases.1,2 dLCD Statement: This policy provides Medicare coverage for APC and MUTYH gene testing for individuals suspected to have Familial Adenomatous

   https://www.amp.org/AMP/assets/File/position-statements/2016/AMP-CAPComments_APC...
10. 240.
    Important issues to consider before interpreting and applying Ct values in...

    groups overlapped by 20-50%. While there are some available prognostic correlates of Ct value within large populations, the variety of SARS-CoV-2 testing procedures and lack of a universally applicable threshold present barriers to the use of Ct values for individualized patient care. Validation or Verification of test performance is central to reporting of

    https://www.amp.org/about/newsroom/amp-blog-content/important-issues-to-consider...